Number of patients with SLE and pSS having various combinations of detectable IgA, IgG and IgM autoantibodies
| Ro 52 kDa | Ro 60 kDa | La | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG/IgM2-150 | IgA†n (%) | IgG/IgM | IgA n (%) | IgG/IgM | IgA n (%) | ||||||
| positivity | n | positivity | n | positivity | n | ||||||
| SLE | +/+ | 19 | 19 (100) | +/+ | 6 | 6 (100) | +/+ | 18 | 17 | ||
| +/− | 5 | 2 (40) | +/− | 10 | 6 (60) | +/− | 3 | 3 | |||
| −/+ | 2 | 1 (50) | −/+ | 1 | 0 (0) | −/+ | 3 | 0 | |||
| −/− | 4 | 0 (0) | −/− | 13 | 2 (15) | −/− | 6 | 0 | |||
| pSS | +/+ | 19 | 19 (100) | +/+ | 5 | 4 (8) | +/+ | 19 | 19 | ||
| +/− | 2 | 2 (100) | +/− | 9 | 8 (89) | +/− | 1 | 1 | |||
| −/+ | 0 | 0 (0) | −/+ | 1 | 1 (100) | −/+ | 0 | 0 | |||
| −/− | 4 | 0 (0) | −/− | 10 | 0 (0) | −/− | 5 | 0 | |||
↵2-150 Indicates the number of patients (n) with detectable levels of IgG and/or IgM autoantibodies (that is, ⩾1+ reactivity in immunoblotting). †Indicates the number of patients (n) with detectable IgA autoantibodies.